Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study
Publication Type:
Journal Article
Authors:
Dieterich, D.;
J K Rockstroh;
Orkin, C.;
Gutierrez, F.;
Klein, M.B.;
Reynes, J.;
Shukla, U.;
Jenkins, A.;
Oliver Lenz;
S Owerkerk-Mahadevan;
Peeters, M.;
De La Rosa, G.;
Tambuyzer, L.;
Jessner, W.Source:
Clin Infect Dis, Volume 59, Issue 11, p.1579-1587 (2014)
Keywords:
Antiretroviral,
Antiretroviral Therapy,
Belgium,
Canada,
chronic HCV,
clinical trial,
Clinical Trials,
coinfection,
Disease,
Fatigue,
France,
Genotype,
genotype 1,
Germany,
HCV,
Headache,
Health,
hepatitis,
Hepatitis C,
hepatitis C virus,
Hiv,
Hiv-1,
Human,
Infection,
interferon,
Liver,
London,
Medicine,
methods,
Nausea,
Neutropenia,
New Jersey,
New York,
Patients,
pegylated,
pegylated interferon,
protease inhibitor,
Research,
RGT,
Safety,
simeprevir,
Spain,
sustained virologic response,
therapy,
treatment,
treatment-naive,
Universities
